Brigatinib vs Alectinib for ALK-Positive NSCLC After Disease Progression on Crizotinib
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Thoracic Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brigatinib Versus Alectinib in ALK-positive Non-small Cell Lung Cancer After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial
J Thorac Oncol 2023 Aug 11;[EPub Ahead of Print], J Chih-Hsin Yang, G Liu, S Lu, J He, M Burotto, MJ Ahn, DW Kim, X Liu, Y Zhao, S Vincent, J Yin, X Ma, HM Lin, S PopatFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.